Nuvalent, Inc. Files 2024 10-K Annual Report

Ticker: NUVL · Form: 10-K · Filed: Feb 27, 2025 · CIK: 1861560

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

Related Tickers: NUVAL

TL;DR

Nuvalent dropped its 2024 10-K. Check financials for 2021-2024.

AI Summary

Nuvalent, Inc. filed its 2024 10-K on February 27, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, based in Cambridge, MA, operates in the pharmaceutical preparations sector. Key financial data and operational details for the fiscal years 2021 through 2024 are presented in this comprehensive annual report.

Why It Matters

This filing provides investors and stakeholders with a detailed overview of Nuvalent's financial health, strategic initiatives, and risk factors for the past fiscal year, crucial for understanding the company's performance and future outlook.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Nuvalent faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in its 10-K filing.

Key Numbers

Key Players & Entities

FAQ

What is Nuvalent, Inc.'s primary business activity?

Nuvalent, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code 2834.

When was the 10-K filing submitted to the SEC?

The 10-K filing was submitted to the SEC on February 27, 2025.

What fiscal year does this 10-K report cover?

This 10-K report covers the fiscal year ending December 31, 2024.

Where is Nuvalent, Inc. headquartered?

Nuvalent, Inc.'s business address is located at One Broadway, 14th Floor, Cambridge, MA 02142.

What is the SEC file number for Nuvalent, Inc.?

The SEC file number for Nuvalent, Inc. is 001-40671.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 27, 2025 regarding Nuvalent, Inc. (NUVL).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing